Evidence map›Paper›PMID 25029497›Full record

ArticlePloS one2014

FBXO7 Y52C polymorphism as a potential protective factor in Parkinson's disease.

Chiung-Mei Chen, I-Cheng Chen, Yi-Cheng Huang, Hsueh-Fen Juan, Ying-Lin Chen, Yi-Chun Chen, Chih-Hsin Lin, Li-Ching Lee, Chi-Mei Lee, Guey-Jen Lee-Chen and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Mitochondrial Biology and Neurological Diseases.Current neuropharmacology · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Chiung-Mei ChenDepartment of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.
I-Cheng ChenDepartment of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.
Yi-Cheng HuangDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Hsueh-Fen JuanDepartment of Life Science, National Taiwan University, Taipei, Taiwan.
Ying-Lin ChenDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Yi-Chun ChenDepartment of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.
Chih-Hsin LinDepartment of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.
Li-Ching LeeDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Chi-Mei LeeDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Guey-Jen Lee-ChenDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Yun-Ju LaiDepartment of Life Science, National Taiwan Normal University, Taipei, Taiwan.
Yih-Ru WuDepartment of Neurology, Chang-Gung Memorial Hospital, Chang-Gung University College of Medicine, Taipei, Taiwan.
National Taiwan Normal University · TWChang Gung Memorial Hospital · TWChang Gung University · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mutations in the F-box only protein 7 gene (FBXO7), the substrate-specifying subunit of SCF E3 ubiquitin ligase complex, cause Parkinson's disease (PD)-15 (PARK15). To identify new variants, we sequenced FBXO7 cDNA in 80 Taiwanese early onset PD patients (age at onset ≤ 50) and only two known variants, Y52C (c.155A>G) and M115I (c.345G>A), were found. To assess the association of Y52C and M115I with the risk of PD, we conducted a case-control study in a cohort of PD and ethnically matched controls. There was a nominal difference in the Y52C G allele frequency between PD and controls (p = 0.045). After combining data from China [1], significant difference in the Y52C G allele frequency between PD and controls (p = 0.012) and significant association of G allele with decreased PD risk (p = 0.017) can be demonstrated. Upon expressing EGFP-tagged Cys52 FBXO7 in cells, a significantly reduced rate of FBXO7 protein decay was observed when compared with cells expressing Tyr52 FBXO7. In silico modeling of Cys52 exhibited a more stable feature than Tyr52. In cells expressing Cys52 FBXO7, the level of TNF receptor-associated factor 2 (TRAF2) was significantly reduced. Moreover, Cys52 FBXO7 showed stronger interaction with TRAF2 and promoted TRAF2 ubiquitination, which may be responsible for the reduced TRAF2 expression in Cys52 cells. After induced differentiation, SH-SY5Y cells expressing Cys52 FBXO7 displayed increased neuronal outgrowth. We therefore hypothesize that Cys52 variant of FBXO7 may contribute to reduced PD susceptibility in Chinese.

Indexed as

Polymorphism, Single Nucleotide1-Methyl-4-phenylpyridiniumAdultAmino Acid SequenceAnimalsCase-Control StudiesCell Line, TumorCell SurvivalF-Box ProteinsFemaleGene Expression RegulationGenetic Predisposition to DiseaseHumansMaleMiddle AgedModels, Molecular1-Methyl-4-phenylpyridiniumF-Box ProteinsFBXO7 protein, humanTNF Receptor-Associated Factor 2

Identifiers

PMID25029497
PMCPMC4100735
OpenAlexW2005882732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.